title: [Pronostic factors on recurrence and progression of superficial bladder cancer. Risk groups (part II)].
abstract: BACKGROUND
  We try to establish risk groups combining the characteristics of each bladder tumour, for a better monitoring of these patients.
  
  
  METHODS
  Once known the variables implied in recurrence and progression we analyze the data to establish the extreme groups, so, the one with the worse and the one with the better prognostic, remaining a residual group that would correspond of the tumours of intermediate prognostic.
  
  
  RESULTS
  From the results obtained, we can establish three risk groups: Bad prognostic group (high risk) : High grade tumours (G3), isolated or associated Tis and multiple or recurrent grade 2 tumours that were recurred in less than 6 months; Intermediate prognostic group: multiple TaG1 tumours, as well as not multiple Ta-1G2 and T1GI (less than 3 tumours) and Group of low risk: Single TaG1 tumours.
  
  
  CONCLUSIONS
  According to these results the group of badly risk, involves a high risk of recurrence and progression. The most effective treatment was the BCG (bacillus Calmette-Guerin) with maintenance, requiring a long-term control, more intense in the 2 first years after the RTU. In the group of intermediate risk, the rates of long-term superficial recurrence were as high as those of the high risk group, being needed a long-term control, in this group was effective the treatment with chemotherapy or BCG being preferably the maintenance. Finally in the group of good risk we don't objectify progressions being the time to the recurrence the longest one, with stabilization of the rate of recurrences after one year.
authors.affiliation: Servicio de Urología I, Hospital Central de Asturias, Departamento de Especialidades Médico-Quirúrgicas, Facultad de Medicina, Universidad de Oviedo, Oviedo. jgrmed@hotmail.com
authors.forename: J
authors.initials: J
authors.lastname: García Rodríguez
authors.forename: J M
authors.initials: JM
authors.lastname: Fernández Gómez
authors.forename: S
authors.initials: S
authors.lastname: Escaf Barmadah
authors.forename: A
authors.initials: A
authors.lastname: Jalón Monzón
authors.forename: M
authors.initials: M
authors.lastname: Alvarez Múgica
authors.forename: J
authors.initials: J
authors.lastname: Regadera Sejas
mesh_terms: D002295:Carcinoma, Transitional Cell / Q000473:pathology* / Q000628:therapy; D018450:Disease Progression; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology*; D011379:Prognosis; D012307:Risk Factors; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000473:pathology* / Q000628:therapy